Darmstadt, Germany, February 10, 2025 – Merck KGaA (“Merck”) reacts to pressreports and confirms advanced discussions with SpringWorks Therapeutics, Inc..Merck also confirms that no legally binding agreement has been entered into. Thereis no certainty that any transaction will materialize. Furthermore, critical conditionshave yet to be met.
End of inside information
About Merck
Merck, a leading science and technology company, operates across life science, healthcare andelectronics. Around 63,000 employees work to make a positive difference to millions of people’s livesevery day by creating more joyful and sustainable ways to live. From providing products and servicesthat accelerate drug development and manufacturing as well as discovering unique ways to treat themost challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023,Merck generated sales of € 21 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological andscientific advances. This is how Merck has thrived since its founding in 1668. The founding family remainsthe majority owner of the publicly listed company. Merck holds the global rights to the Merck name andbrand. The only exceptions are the United States and Canada, where the business sectors of Merckoperate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merckwebsite. Please go to www.merckgroup.com/subscribe to register online, change your selection ordiscontinue this service.